Development of a novel cancer pain treatment based on the daily rhythm of biological signals.

2022 Fiscal Year Final Research Report

• Project/Area Number: 19K16466
• Research Category: Grant-in-Aid for Early-Career Scientists
• Allocation Type: Multi-year Fund
• Review Section: Basic Section 47060:Clinical pharmacy-related
• Research Institution: Daiichi University, College of Pharmaceutical Sciences
• Principal Investigator: Okazaki Hiroyuki 第一薬科大学, 薬学部, 講師 (50734125)
• Project Period (FY): 2019-04-01 – 2023-03-31
• Keywords: がん / mTOR

Outline of Final Research Achievements

Everolimus and Temsirolimus, drugs that inhibit mTOR signaling, altered the expression of clock genes in tumor cells. Temsirolimus had an inhibitory effect on factors affecting the expression of cancer pain, on the other hand, Everolimus didn’t show that. While the expression of the pain factor Trpv1 fluctuates cyclically in normal tumor cells, the fluctuation was suppressed by Temsirolimus. Although the results suggest that mTOR and Trpv1 expression changes may be useful for pain control, the difference in responsiveness between the two drugs needs to be investigated in detail.

Free Research Field

がん

Academic Significance and Societal Importance of the Research Achievements

本研究で得られた成果は、mTOR阻害によるTrpv1を介した疼痛コントロールへの新たなアプローチについて、体内時計機構を加味した研究の有用性と必要性を提示するものである。さらに研究が進展し、詳細なメカニズムが解明されることで、より特異的に疼痛を抑制する新たな化合物や薬剤の探索が進み、臨床への応用が期待される。